Longer Duration of Statin Use Linked to Lower Risk for Glaucoma
Self-reported high cholesterol levels without statin use tied to higher glaucoma risk
Glaucoma
Rocklatan Approved to Reduce IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension
The Food and Drug Administration (FDA) has approved Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution; Aerie) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Xelpros Approved for Open-Angle Glaucoma, Ocular Hypertension
Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor.
Implant to Reduce Intraocular Pressure in Glaucoma Shows Promise
The trial included 594 individuals with open-angle glaucoma or ocular hypertension. Participants were randomized to receive 3 administration cycles (Day 1, Week 16 and Week 32) of Bimatoprost SR or twice daily timolol eye drops.
Rhopressa Now Available for Open-Angle Glaucoma, Ocular Hypertension
The approval was based on results from 3 randomized trials which found that Rhopressa was associated with a reduction in intraocular pressure of up to 5mmHg.
Static Perimetry Test May Benefit Children With Glaucoma
“A simple static perimetry approach potentially yields high-quality results in children younger than 10 years,” the authors write.
Novel Once-Daily Eye Drop Approved for Lowering Elevated IOP in Glaucoma
Rhopressa (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Beverage Consumption Linked to Lower Glaucoma Odds
There were no significant associations between glaucoma and consumption of caffeinated and decaffeinated coffee, iced tea, and soft drinks.
Vyzulta Approved to Treat Patients With Open-Angle Glaucoma, Ocular HTN
Vyzulta works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm’s canal.
Recall of Two Glaucoma Medications Announced
The recall applies to Combigan 0.2%/0.5% lots in 2.5mL, 5mL, 10mL and 15mL sizes, and one lot of Lumigan 0.01%.
